Putting Patients First Blog

SEPTEMBER 3, 2024

The NHC appreciates CMS’ efforts to gather patient-centered data as part of this ICR and its commitment to making the process more relevant for patients and patient organizations. While we acknowledge these improvements, it is important to note that some aspects of the data collection process may remain challenging.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling Communication 52

Pharma Marketing Network

FEBRUARY 5, 2025

The real challenge lies in ensuring it reaches the right patients at the right time and at an affordable price. Pharmaceutical market access refers to the process of ensuring a drug is not only approved but also commercially viable, reimbursed, and accessible to patients. Early negotiation of coverage agreements.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 52

Big Molecule Watch

AUGUST 25, 2023

The Inflation Reduction Act’s Medicare Drug Price Negotiation Program will kick off next week. There are reports that the White House may announce the list of selected drugs even before that deadline, on Tuesday, August 29 th. Before the IRA, the government could not set prices for any drugs covered by Medicare.

Drug Pricing 40

Drug Pricing Biosimilars Insurance Coverage and Processing Labelling 40

Putting Patients First Blog

JANUARY 27, 2025

However, the scope and complexity of the proposed rule may present implementation challenges. Coverage of Anti-Obesity Medications (AOMs) The NHC applauds CMS for aligning with the medical community and proposing to recognize obesity as a chronic disease and allow Medicare Part D coverage for AOMs.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

STAT

MARCH 26, 2024

The evidence presented itself early this morning as the official mascots dashed about the grounds to bark about passersby, and a steady parade of driving machines could be seen from our window. ” While out-of-pocket caps on insulin indeed cut down on costs for commercially insured patients in the U.S.,

Drug Pricing 256

Drug Pricing Insurance Coverage and Processing Diabetes Pharmaceutical Companies 256

Pharmaceutical Technology

FEBRUARY 7, 2023

Launching a new drug can be a risky business, with regulatory approval no guarantee that private, commercial, and government-funded insurers will reimburse it. In Europe, the pricing and reimbursement (P&R) of pharmaceuticals is governed by individual member states.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Inpatient Drug Pricing Packaging 52

Proxsys Rx

AUGUST 16, 2023

In the column, Hassell calls-attention to an earlier op-ed column published by The Hill as “yet another example of a drug company-focused view on the 340B Drug Pricing Program, couched in the language of reform.” “Its First, start with presenting drug company-funded research as if it is non-biased.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Hospitals Drug Pricing Pharmaceutical Companies 52